PAUL A. WENDER
BERGSTROM PROFESSOR OF CHEMISTRY
PROFESSOR OF CHEMICAL AND SYSTEMS BIOLOGY
STANFORD UNIVERSITY

Paul Wender is the Bergstrom Professor of Chemistry at Stanford University, Professor of Chemical and Systems Biology (by courtesy, Stanford Medical School), a cofounder of the Quantitative Chemical Biology Program, on the advisory committees of the Stanford Molecular Imaging Program and the Stanford Institute for Chemical Biology, and is affiliated with the Bio-X Program, the Center for Molecular Analysis and Design, the Program for Molecular and Genetic Medicine, the Comprehensive Cancer Center, the Cancer Pharmacology Program, the Cancer Nanotechnology Program, the Molecular Therapeutics Program, and the National Translation Research Initiative. He was also a cofounder, science advisor and board member of CellGate, a now acquired biotech company that pioneered new strategies for drug delivery, and has contributed to the founding of other biotech companies focused on therapeutic leads developed in his laboratories. He serves on numerous science advisory boards including the non-profit Lilly TB Drug Discovery Initiative, the Vanderbilt Institute of Chemical Biology, the Burnham Institute, the Rockefeller Neurosciences Institute, the SUNY Upstate Cancer Research Institute, and the Institut des Biomolecules Max Mousseron (France). His research involves studies in chemistry, biology, medicine, and materials science. His group is interested in the design and mechanism of action of molecules that exhibit unique biological activity and transformative, first-in-class therapeutic potential. His group has developed fundamentally new ways of synthesizing such compounds with an emphasis on the "Ideal Synthesis", "step economy", and "function oriented synthesis and design". His group has introduced over 25 new reactions, has completed the first and/or shortest syntheses of numerous major synthetic and therapeutic targets (including taxol, phorbol, bryostatin-9, resiniferatoxin, etc), and has advanced therapeutic leads and drug delivery systems (e.g., arginine-rich molecular transporters) into human clinical trials. Current research involves synthesis studies with an emphasis on transformative strategies and new reactions, and novel chemistry driven approaches to imaging, diagnostics, drug delivery, cancer and disease resistance, immunotherapy, HIV/AIDS eradication, and Alzheimer's disease. The work of his group is described in over 290 publications and over 20 issued or pending patents.

Professor Wender is a member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences and a Fellow of the American Association of Arts and Sciences. His work has been recognized with numerous awards, including the Dreyfus Teacher Scholar Award, Sloan Fellowship Award, Eli Lilly Grantee Award, Ernest Guenther Award of the American Chemical Society, Pfizer Research Award for Synthetic Organic Chemistry, American Chemical Society Award for Creative Work in Synthetic Organic Chemistry, the ICI Pharmaceutical Group's Stuart Award for Excellence in Chemistry, Arthur C. Cope Scholar Award, National Science Foundation Award for Special Creativity, two National Institutes of Health Merit Awards (**1993**, **2006**), Alexander von Humboldt Stiftung Award, the American Chemical Society H. C. Brown Award for Creative Research in Synthetic Methods, the Wilbur Cross Medal of Yale University, an honorary doctorate from the University of Montpellier (France, **2012**), and the **2013** Tetrahedron Prize For Creativity in Organic Chemistry. He has been recognized for his teaching as well with the first Associated Stanford Students Union Teaching Award, the Hoagland Prize for Undergraduate Teaching, the Bing Teaching Award, and the Dean's Distinguished Teaching Award from Stanford University. He has lectured extensively (>350) as a named, plenary or keynote speaker. Professor Wender has served as a consultant to various pharmaceutical companies, on various editorial advisory boards and on science advisory boards of several companies, institutes and universities. He is a former editor of *Synthesis* and has served on the Chemistry Advisory Boards to the National Science Foundation and the American Association for Cancer Research, as Chairman of the National Institutes of Health Medicinal Chemistry Study Section, the NIH Synthetic and Biological Chemistry Study Section, and the NIH Taxol Study Section and is currently a member of the NIH College of CSR reviewers.